Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,549.80GBp
20 Jul 2018
Change (% chg)

-8.20 (-0.53%)
Prev Close
1,558.00
Open
1,561.20
Day's High
1,561.60
Day's Low
1,538.00
Volume
8,774,063
Avg. Vol
8,805,731
52-wk High
1,632.00
52-wk Low
1,235.20

Latest Key Developments (Source: Significant Developments)

Glaxosmithkline Says U.S. FDA Approves Krintafel For Radical Cure Of P. Vivax Malaria
Friday, 20 Jul 2018 

July 20 (Reuters) - GlaxoSmithKline PLC ::US FDA APPROVES KRINTAFEL (TAFENOQUINE) FOR RADICAL CURE OF P. VIVAX MALARIA.  Full Article

GSK Board Considers Break-Up Of Group - FT
Friday, 20 Jul 2018 

July 20 (Reuters) - :GSK BOARD CONSIDERS BREAK-UP OF GROUP, CHAIRMAN WEIGHS SPINNING OFF CONSUMER DIVISION AFTER PRESSURE FROM INVESTORS - FT, CITING SOURCES.  Full Article

GlaxoSmithKline Says James Ford Appointed General Counsel
Thursday, 12 Jul 2018 

July 12 (Reuters) - GlaxoSmithKline PLC ::JAMES FORD APPOINTED GSK GENERAL COUNSEL.JAMES FORD APPOINTED GSK GENERAL COUNSEL.JAMES REPLACES DAN TROY WHO WILL LEAVE GSK AFTER 10 YEARS AS GENERAL COUNSEL.  Full Article

GlaxoSmithKline Says Signs Deal With Roivant Unit To Purchase Rights To Tapinarof
Thursday, 12 Jul 2018 

July 12 (Reuters) - GlaxoSmithKline PLC ::ROIVANT SUBSIDIARY DERMAVANT SCIENCES SIGNS AGREEMENT WITH GSK TO PURCHASE RIGHTS TO TAPINAROF.TOTAL CONSIDERATION OF £250 MILLION, INCLUDING AN INITIAL PAYMENT OF £150 MILLION AND A POTENTIAL FUTURE MILESTONE PAYMENT OF £100 MILLION.  Full Article

Glaxosmithkline Reports 8.3 Pct Stake In Translate Bio As Of June 27 - Sec FILING
Thursday, 5 Jul 2018 

July 5 (Reuters) - Glaxosmithkline Reports 8.3 Pct Stake In Translate Bio Inc ::GLAXOSMITHKLINE SAYS THROUGH UNIT, ACQUIRED FROM TRANSLATE BIO 269,230 SHARES OF STOCK ON JULY 2 IN TRANSLATE'S IPO AT PUBLIC OFFERING PRICE OF $13.00/SHARE.GLAXOSMITHKLINE REPORTS 8.3 PCT STAKE IN TRANSLATE BIO INC <<>> AS OF JUNE 27 - SEC FILING .  Full Article

FDA Approves First sANDA For Glenmark Pharma's Manufacturing Facility In Monroe
Monday, 18 Jun 2018 

June 18 (Reuters) - Glenmark Pharmaceuticals Ltd ::THE US FDA APPROVES FIRST SUPPLEMENTAL ABBREVIATED NEW DRUG APPLICATION (SANDA) FOR GLENMARK PHARMACEUTICALS' MANUFACTURING FACILITY IN MONROE, NORTH CAROLINA.GLENMARK PHARMA - APPROVAL COVERS ATOVAQUONE & PROGUANIL HYDROCHLORIDE TABLETS, 250 MG/100 MG AND 62.5 MG/25 MG.  Full Article

GSK Submits Regulatory Application In Japan For Once-Daily Single Inhaler Triple Therapy For Patients With COPD
Tuesday, 29 May 2018 

May 29 (Reuters) - GlaxoSmithKline PLC ::GSK ONCE-DAILY SINGLE INHALER TRIPLE THERAPY COPD.SUBMISSION OF A REGULATORY APPLICATION TO JAPANESE MHLW FOR ONCE-DAILY FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL.NEW DRUG APPLICATION IS PRIMARILY BASED ON DATA FROM PHASE III IMPACT STUDY WHICH INCLUDED 378 PATIENTS FROM JAPAN.  Full Article

GlaxoSmithKline Says ViiV Granted EU Marketing Authorisation For Juluca
Monday, 21 May 2018 

May 21 (Reuters) - GlaxoSmithKline PLC ::VIIV GRANTED EU MARKETING AUTHORISATION FOR JULUCA.VIIV HEALTHCARE RECEIVES EU MARKETING AUTHORISATION FOR JULUCA FIRST 2-DRUG REGIMEN, ONCE-DAILY, SINGLE-PILL FOR TREATMENT OF HIV.  Full Article

GlaxoSmithKline Says Nucala Study Reports Long-Term Safety Data, Consistent Exacerbation Reduction, Improved Asthma Control
Monday, 21 May 2018 

May 21 (Reuters) - GlaxoSmithKline PLC ::NUCALA (MEPOLIZUMAB) STUDY REPORTS LONG-TERM SAFETY DATA, CONSISTENT EXACERBATION REDUCTION AND IMPROVED ASTHMA CONTROL.NEW STUDY SHOWED ONE THIRD OF PATIENTS HAD NO EXACERBATIONS ON LONG-TERM TREATMENT WITH NUCALA.  Full Article

GlaxoSmithKline CFO Simon Dingemans To Retire From Company
Wednesday, 9 May 2018 

May 9 (Reuters) - GlaxoSmithKline PLC ::SIMON DINGEMANS, CHIEF FINANCIAL OFFICER (CFO), GSK, HAS INFORMED BOARD OF HIS INTENTION TO RETIRE FROM COMPANY.BOARD WILL NOW CONDUCT A THOROUGH GLOBAL SEARCH BOTH INTERNALLY AND EXTERNALLY TO IDENTIFY A SUCCESSOR..  Full Article

Photo

GlaxoSmithKline considers splitting up the group - FT

GlaxoSmithKline Plc is considering a break-up of the group after investors pressed the company's board to spin off its consumer division, the Financial Times reported on Friday.